The estimated Net Worth of John D Forsyth is at least $1.42 Milion dollars as of 1 April 2022. Mr. Forsyth owns over 1,005 units of Baxter International stock worth over $1,100,895 and over the last 21 years he sold BAX stock worth over $0. In addition, he makes $320,944 as Independent Director at Baxter International.
Sign up
Mr. Forsyth BAX stock SEC Form 4 insiders trading
John has made over 19 trades of the Baxter International stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 1,005 units of BAX stock worth $29,668 on 1 April 2022.
The largest trade he's ever made was exercising 11,610 units of Baxter International stock on 28 July 2011 worth over $358,865. On average, John trades about 1,344 units every 100 days since 2003. As of 1 April 2022 he still owns at least 28,034 units of Baxter International stock.
You can see the complete history of Mr. Forsyth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Forsyth biography
John D. Forsyth is an Independent Director of the Company. Mr. Forsyth has been Chairman of Wellmark Blue Cross Blue Shield, a healthcare insurance provider for residents of Iowa and South Dakota, since 2000 and Chief Executive Officer since 1996. Prior to that, he spent 26 years at the University of Michigan, holding various positions, including President and Chief Executive Officer of the University of Michigan Health System. Mr. Forsyth currently serves as a director of the National Institute of Healthcare Management and previously served as a director of Baxalta, before it was acquired by Shire plc (Shire) in June 2016 and before Shire was acquired by Takeda Pharmaceutical Company in 2019.
What is the salary of John Forsyth?
As the Independent Director of Baxter International, the total compensation of John Forsyth at Baxter International is $320,944. There are 18 executives at Baxter International getting paid more, with Jose Almeida having the highest compensation of $13,913,800.
How old is John Forsyth?
John Forsyth is 72, he's been the Independent Director of Baxter International since 2003. There are 2 older and 26 younger executives at Baxter International. The oldest executive at Baxter International Inc. is James Gavin, 74, who is the Independent Director.
What's John Forsyth's mailing address?
John's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Insiders trading at Baxter International
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney oraz Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
What does Baxter International do?
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
What does Baxter International's logo look like?
Complete history of Mr. Forsyth stock trades at Baxter International
Baxter International executives and stock owners
Baxter International executives and other stock owners filed with the SEC include:
-
Jose Almeida,
Chairman of the Board, President, Chief Executive Officer -
James Saccaro,
Chief Financial Officer, Executive Vice President -
Jeanne Mason,
Senior Vice President - Human Resources -
Giuseppe Accogli,
Senior Vice President, President- America -
Sean Martin,
Senior Vice President, General Counsel -
Cristiano Franzi,
Senior Vice President and President, EMEA -
Jose E. Almeida,
Chairman, Pres & CEO -
Cristiano Franzi,
Sr. VP & Pres for EMEA -
Giuseppe Accogli,
Exec. VP & COO -
James K. Saccaro,
Exec. VP & CFO -
Sean B. W. Martin,
Sr. VP & Gen. Counsel -
Thomas Stallkamp,
Lead Independent Director -
Albert Stroucken,
Independent Director -
Peter Hellman,
Independent Director -
James Gavin,
Independent Director -
Patricia Morrison,
Independent Director -
Stephen Oesterle,
Independent Director -
Amy Wendell,
Independent Director -
John Forsyth,
Independent Director -
Michael Mahoney,
Independent Director -
Cathy Smith,
Independent Director -
Thomas Chen,
Independent Director -
Jacqueline Kunzler,
Senior Vice President and Chief Quality Officer -
Andrew Frye,
Senior Vice President and President, APAC -
Brian Stevens,
Senior Vice President, Chief Accounting Officer, Controller -
David S. Rosenbloom,
Sr. VP & Gen. Counsel -
Clare Trachtman,
VP of Investor Relations -
Brian C. Stevens,
Sr. VP, Chief Accounting Officer & Controller -
Wilber C. Boren IV,
Pres of Advanced Surgery -
Andrew Frye,
Sr. VP & Pres of APAC -
Jeanne K. Mason,
Sr. VP of HR -
Stacey Eisen,
Sr. VP of Global Communications -
Talvis P. Love,
Sr. VP & Chief Information Officer -
David P. Scharf,
Corporate Vice President -
Kees J Storm,
Director -
Marcus Schabacker,
CVP, Chief Scientific Officer -
Robert Felicelli,
CVP, Quality -
Brik V Eyre,
CVP, Hospital Products -
Carole J Uhrich,
Director -
Paul Vibert,
CVP, International -
Scott Pleau,
CVP - Operations -
Caroline Karp,
CVP, Controller -
Point Llc Loeb Daniel S Third,
-
Christopher A. Toth,
EVP,Group Pres, Kidney Care -
William A. Ii Ampofo,
Director -
Steven Flynn,
SVP, President, APAC -
Peter M Wilver,
Director -
David Brent Shafer,
Director -
Thomas J Jr Sabatino,
Senior Vice President -
Yuan Chia Pei,
Director -
Cheryl L White,
Corporate Vice President -
Joy A Amundson,
Corporate Vice President -
Jill M Schaaf,
CVP, Renal -
Harry M Jansen Jr Kraemer,
Chairman and -
Robert J. Hombach,
Corporate Vice President & CFO -
James E Utts,
Corporate Vice President -
Uma Chowdhry,
Director -
Peter J Arduini,
Corporate Vice President -
Bruce Mc Gillivray,
Corporate Vice President -
Sebastian J Bufalino,
Corporate Vice President -
Jean Luc Butel,
Corporate Vice President -
James M Gatling,
Corporate Vice President -
John C Moon,
Corporate Vice President -
Salto Carlos Del,
Senior Vice President -
Wayne T Hockmeyer,
Director -
Joseph B Martin,
Director -
Michael J Baughman,
Corporate Vice President -
Steven J Meyer,
Treasurer -
Michael J Tucker,
Senior Vice President -
James R Hurley,
Corporate Vice President -
Monroe E Trout,
Director -
Thomas Fang Tyan Chen,
Director -
Nevelle J Jeharajah,
Corporate Vice President -
Robert M Davis,
Corp. VP, CFO and Treasurer -
Jan Stern Reed,
Corporate Secretary -
Thomas H Glanzmann,
Senior Vice President -
Walter E Boomer,
Director -
Gail D Fosler,
Director -
Phillip L. Batchelor,
Corporate Vice President -
Karenann K Terrell,
Corporate Vice President -
Robert L Jr Parkinson,
Chairman of the Board and -
Karen J May,
Corporate Vice President -
Timothy P Lawrence,
CVP, Operations -
Blake E Devitt,
Director -
John J Greisch,
Senior Vice President & CFO -
Munib Islam,
Director -
Gregory P Young,
Corporate Vice President -
Susan R Lichtenstein,
Corporate Vice President, -
Lawrence T Gibbons,
Corporate Vice President -
David F Drohan,
Senior Vice President -
Fred L Turner,
Director -
Norbert G Riedel,
Corporate Vice President -
Brian P Anderson,
Senior Vice President -
Ludwig Hantson,
Corporate Vice President -
David S. Wilkes,
Director -
Nancy M Schlichting,
Director -
Joel T. Grade,
EVP and CFO -
Alok Sonig,
EVP,Group President, Pharma -
David S. Rosenbloom,
EVP and General Counsel -
Heather Knight,
EVP,Group Pres,Med Products -
Reazur Rasul,
EVP,Group Pres, Healthcare -
Jeffrey A Craig,
Director -
Stephen H Rusckowski,
Director -
James W Borzi,
EVP,Chief Supply Chain Officer